Acquired chemotherapy resistance in ovarian cancer

EL Christie; DDL Bowtell

Journal article

Acquired chemotherapy resistance in ovarian cancer

EL Christie, DDL Bowtell

Annals of Oncology | OXFORD UNIV PRESS | Published : 2017

DOI: 10.1093/annonc/mdx446

University of Melbourne Researchers

David Bowtell Author The Sir Peter MacCallum Department of Oncology

Elizabeth Christie Author The Sir Peter MacCallum Department of Oncology

Related Projects (3)

UNDERSTANDING AND TARGETING ACQUIRED CHEMORESISTANCE IN HIGH-GRADE SEROUS OVARIAN CANCER

We recently discovered a mutation in recurrent high-grade serous ovarian cancer that causes profound overexpression of the multidrug resista..

CLINICAL TRANSLATION OF A NEWLY DISCOVERED TRANSCRIPTIONAL FUSION INVOLVING THE MULTIDRUG RESISTANCE TRANSPORTER (ABCB1) IN RECURRENT DRUG RESISTANT OVARIAN CANCER

IMPROVING OUTCOMES FOR WOMEN WITH EPITHELIAL OVARIAN CANCER

nan

Grants

Awarded by National Health and Medical Research Council (NHMRC)

Awarded by NHMRC

Awarded by Victorian Cancer Agency

Awarded by U.S. Army Medical Research and Materiel Command

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Funding Acknowledgements

This work was supported by a National Health and Medical Research Council (NHMRC) program grant (APP1092856; to D.D.L. Bowtell), NHMRC project grant (GNT1124309; to E. Christie) and a Victorian Cancer Agency Early Career Seed Grant (ECSG15012; to E. Christie). The Australian Ovarian Cancer Study is supported by the Peter MacCallum Cancer Centre Foundation, U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania, and the National Health and Medical Research Council of Australia (NHMRC; ID#628779), and Ovarian Cancer Australia. The publication of this supplement and the symposium on which it is based have been supported through partnership between the Spanish Ovarian Cancer Research Group (GEICO) and the European Society for Medical Oncology (ESMO).